Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) Equity Average (2016 - 2025)

Macrogenics (MGNX) has disclosed Equity Average for 10 consecutive years, with $118.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Equity Average fell 31.87% to $118.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $118.1 million, a 31.87% decrease, with the full-year FY2025 number at $85.8 million, down 36.11% from a year prior.
  • Equity Average was $118.1 million for Q4 2024 at Macrogenics, down from $129.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $305.2 million in Q3 2021 to a low of $118.1 million in Q4 2024.
  • A 5-year average of $186.9 million and a median of $178.0 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: tumbled 56.52% in 2022, then soared 37.71% in 2023.
  • Macrogenics' Equity Average stood at $219.2 million in 2020, then increased by 21.15% to $265.5 million in 2021, then crashed by 50.1% to $132.5 million in 2022, then skyrocketed by 30.8% to $173.3 million in 2023, then plummeted by 31.87% to $118.1 million in 2024.
  • Per Business Quant, the three most recent readings for MGNX's Equity Average are $118.1 million (Q4 2024), $129.4 million (Q1 2024), and $173.3 million (Q4 2023).